Orgovyx

Overview

relugolix

GnRH antagonist

• CYP3A4 substrate
• P-gp substrate
• GnRH receptor antagonist
• prolongs QT interval (conditional)

Contraindicated

• pimozide
Orgovyx (relugolix)

+

pimozide

1 interaction

Contraindicated

relugolix + pimozide

contraindicated if prostate cancer use: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• thioridazine
Orgovyx (relugolix)

+

thioridazine

1 interaction

Contraindicated

relugolix + thioridazine

contraindicated if prostate cancer use: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

Avoid/Use Alternative

• abrocitinib
Orgovyx (relugolix)

+

abrocitinib

1 interaction

Avoid/Use Alternative

relugolix + abrocitinib

PROSTATE CANCER: may hold relugolix if abrocitinib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before abrocitinib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before abrocitinib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• adagrasib
Orgovyx (relugolix)

+

adagrasib

1 interaction

Avoid/Use Alternative

relugolix + adagrasib

PROSTATE CANCER: may hold relugolix if adagrasib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before adagrasib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before adagrasib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited; additive effects, androgen deprivation may prolong QT)

• aficamten
Orgovyx (relugolix)

+

aficamten

1 interaction

Avoid/Use Alternative

relugolix + aficamten

PROSTATE CANCER: may hold relugolix if aficamten tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before aficamten; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before aficamten: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• amiodarone
Orgovyx (relugolix)

+

amiodarone

1 interaction

Avoid/Use Alternative

relugolix + amiodarone

PROSTATE CANCER, ORAL AMIODARONE: may hold relugolix if amiodarone tx up to 2wk; otherwise, use alternative or admin. relugolix at least 6h before amiodarone; monitor ECG, electrolytes; PROSTATE CANCER, IV AMIODARONE: monitor ECG, electrolytes; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before oral amiodarone: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited; additive effects, androgen deprivation may prolong QT)

• apalutamide
Orgovyx (relugolix)

+

apalutamide

1 interaction

Avoid/Use Alternative

relugolix + apalutamide

FIBROID-ASSOC. BLEEDING: avoid combo; PROSTATE CANCER: use alternative or incr. relugolix maint. dose to 240 mg/day; monitor ECG, electrolytes: combo may decr. relugolix levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced, P-gp-mediated transport induced; additive effects, androgen deprivation may prolong QT)

• arsenic trioxide
Orgovyx (relugolix)

+

arsenic trioxide

1 interaction

Avoid/Use Alternative

relugolix + arsenic trioxide

if prostate cancer use, use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• asciminib
Orgovyx (relugolix)

+

asciminib

1 interaction

Avoid/Use Alternative

relugolix + asciminib

PROSTATE CANCER: may hold relugolix if asciminib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before asciminib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before asciminib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport possibly inhibited)

• azithromycin
Orgovyx (relugolix)

+

azithromycin

1 interaction

Avoid/Use Alternative

relugolix + azithromycin

PROSTATE CANCER, ORAL AZITHROMYCIN: may hold relugolix if azithromycin tx up to 2wk; otherwise, use alternative or admin. relugolix at least 6h before azithromycin; monitor ECG, electrolytes; PROSTATE CANCER, IV AZITHROMYCIN: monitor ECG, electrolytes; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before oral azithromycin: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited; additive effects, androgen deprivation may prolong QT)

• bedaquiline
Orgovyx (relugolix)

+

bedaquiline

1 interaction

Avoid/Use Alternative

relugolix + bedaquiline

if prostate cancer use, use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• belumosudil
Orgovyx (relugolix)

+

belumosudil

1 interaction

Avoid/Use Alternative

relugolix + belumosudil

PROSTATE CANCER: may hold relugolix if belumosudil tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before belumosudil; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before belumosudil: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• berotralstat
Orgovyx (relugolix)

+

berotralstat

1 interaction

Avoid/Use Alternative

relugolix + berotralstat

PROSTATE CANCER: may hold relugolix if berotralstat tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before berotralstat; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before berotralstat: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• bisoprolol
Orgovyx (relugolix)

+

bisoprolol

1 interaction

Avoid/Use Alternative

relugolix + bisoprolol

PROSTATE CANCER: may hold relugolix if bisoprolol tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before bisoprolol; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before bisoprolol: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• brigatinib
Orgovyx (relugolix)

+

brigatinib

1 interaction

Avoid/Use Alternative

relugolix + brigatinib

PROSTATE CANCER: may hold relugolix if brigatinib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before brigatinib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before brigatinib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport possibly inhibited)

• butalbital
Orgovyx (relugolix)

+

butalbital

1 interaction

Avoid/Use Alternative

relugolix + butalbital

FIBROID-ASSOC. BLEEDING: if also combined w/ P-gp inducer, avoid combo; otherwise, caution advised; PROSTATE CANCER: if also combined w/ P-gp inducer, use alternative or incr. relugolix maint. dose to 240 mg/day; otherwise, caution advised: combo may decr. relugolix levels, efficacy (hepatic metabolism induced)

• canagliflozin
Orgovyx (relugolix)

+

canagliflozin

1 interaction

Avoid/Use Alternative

relugolix + canagliflozin

PROSTATE CANCER: may hold relugolix if canagliflozin tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before canagliflozin; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before canagliflozin: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• cannabidiol
Orgovyx (relugolix)

+

cannabidiol

1 interaction

Avoid/Use Alternative

relugolix + cannabidiol

PROSTATE CANCER: may hold relugolix if oral cannabidiol tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before oral cannabidiol; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before oral cannabidiol: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• capmatinib
Orgovyx (relugolix)

+

capmatinib

1 interaction

Avoid/Use Alternative

relugolix + capmatinib

PROSTATE CANCER: may hold relugolix if capmatinib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before capmatinib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before capmatinib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• captopril
Orgovyx (relugolix)

+

captopril

1 interaction

Avoid/Use Alternative

relugolix + captopril

PROSTATE CANCER: may hold relugolix if captopril tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before captopril; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before captopril: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• carbamazepine
Orgovyx (relugolix)

+

carbamazepine

1 interaction

Avoid/Use Alternative

relugolix + carbamazepine

FIBROID-ASSOC. BLEEDING: avoid combo; PROSTATE CANCER: use alternative or incr. relugolix maint. dose to 240 mg/day: combo may decr. relugolix levels, efficacy (hepatic metabolism induced, P-gp-mediated transport induced)

• carvedilol
Orgovyx (relugolix)

+

carvedilol

1 interaction

Avoid/Use Alternative

relugolix + carvedilol

PROSTATE CANCER: may hold relugolix if carvedilol tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before carvedilol; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before carvedilol: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• cimetidine
Orgovyx (relugolix)

+

cimetidine

1 interaction

Avoid/Use Alternative

relugolix + cimetidine

PROSTATE CANCER: may hold relugolix if cimetidine tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before cimetidine; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before cimetidine: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• cisapride
Orgovyx (relugolix)

+

cisapride

1 interaction

Avoid/Use Alternative

relugolix + cisapride

if prostate cancer use, use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• clarithromycin
Orgovyx (relugolix)

+

clarithromycin

1 interaction

Avoid/Use Alternative

relugolix + clarithromycin

PROSTATE CANCER: may hold relugolix if clarithromycin tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before clarithromycin; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before clarithromycin: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited; additive effects, androgen deprivation may prolong QT)

• cobicistat
Orgovyx (relugolix)

+

cobicistat

1 interaction

Avoid/Use Alternative

relugolix + cobicistat

PROSTATE CANCER: may hold relugolix if cobicistat tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before cobicistat; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before cobicistat: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• crizotinib
Orgovyx (relugolix)

+

crizotinib

1 interaction

Avoid/Use Alternative

relugolix + crizotinib

if prostate cancer use, use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• cyclosporine
Orgovyx (relugolix)

+

cyclosporine

1 interaction

Avoid/Use Alternative

relugolix + cyclosporine

PROSTATE CANCER: may hold relugolix if oral cyclosporine tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before oral cyclosporine; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before oral cyclosporine: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• danicopan
Orgovyx (relugolix)

+

danicopan

1 interaction

Avoid/Use Alternative

relugolix + danicopan

PROSTATE CANCER: may hold relugolix if danicopan tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before danicopan; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before danicopan: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• danshen
Orgovyx (relugolix)

+

danshen

1 interaction

Avoid/Use Alternative

relugolix + danshen

FIBROID-ASSOC. BLEEDING: if also combined w/ strong CYP3A4 inducer, avoid combo; otherwise, caution advised; PROSTATE CANCER: if also combined w/ strong CYP3A4 inducer, use alternative or incr. relugolix maint. dose to 240 mg/day; otherwise, caution advised: combo may decr. relugolix levels, efficacy (P-gp-mediated transport induced)

• daridorexant
Orgovyx (relugolix)

+

daridorexant

1 interaction

Avoid/Use Alternative

relugolix + daridorexant

PROSTATE CANCER: may hold relugolix if daridorexant tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before daridorexant; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before daridorexant: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• darunavir
Orgovyx (relugolix)

+

darunavir

1 interaction

Avoid/Use Alternative

relugolix + darunavir

PROSTATE CANCER: may hold relugolix if darunavir tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before darunavir; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before darunavir: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• dicloxacillin
Orgovyx (relugolix)

+

dicloxacillin

1 interaction

Avoid/Use Alternative

relugolix + dicloxacillin

FIBROID-ASSOC. BLEEDING: if also combined w/ strong CYP3A4 inducer, avoid combo; otherwise, caution advised; PROSTATE CANCER: if also combined w/ strong CYP3A4 inducer, use alternative or incr. relugolix maint. dose to 240 mg/day; otherwise, caution advised: combo may decr. relugolix levels, efficacy (P-gp-mediated transport induced)

• diltiazem
Orgovyx (relugolix)

+

diltiazem

1 interaction

Avoid/Use Alternative

relugolix + diltiazem

PROSTATE CANCER: may hold relugolix if oral diltiazem tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before oral diltiazem; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before oral diltiazem: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• diosmin
Orgovyx (relugolix)

+

diosmin

1 interaction

Avoid/Use Alternative

relugolix + diosmin

PROSTATE CANCER: may hold relugolix if diosmin tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before diosmin; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before diosmin: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• domperidone
Orgovyx (relugolix)

+

domperidone

1 interaction

Avoid/Use Alternative

relugolix + domperidone

if prostate cancer use, use alternative or monitor ECG, HR, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• dronedarone
Orgovyx (relugolix)

+

dronedarone

1 interaction

Avoid/Use Alternative

relugolix + dronedarone

PROSTATE CANCER: may hold relugolix if dronedarone tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before dronedarone; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before dronedarone: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited; additive effects, androgen deprivation may prolong QT)

• efavirenz
Orgovyx (relugolix)

+

efavirenz

1 interaction

Avoid/Use Alternative

relugolix + efavirenz

FIBROID-ASSOC. BLEEDING: if also combined w/ strong CYP3A4 inducer, avoid combo; otherwise, caution advised; PROSTATE CANCER: if also combined w/ strong CYP3A4 inducer, use alternative or incr. relugolix maint. dose to 240 mg/day; otherwise, caution advised: combo may decr. relugolix levels, efficacy (hepatic metabolism induced, P-gp-mediated transport induced)

• elacestrant
Orgovyx (relugolix)

+

elacestrant

1 interaction

Avoid/Use Alternative

relugolix + elacestrant

PROSTATE CANCER: may hold relugolix if elacestrant tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before elacestrant; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before elacestrant: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• elexacaftor/tezacaftor/ivacaftor
Orgovyx (relugolix)

+

elexacaftor/ tezacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

relugolix + elexacaftor/ tezacaftor/ ivacaftor

PROSTATE CANCER: may hold relugolix if elexacaftor/tezacaftor/ivacaftor tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before elexacaftor/tezacaftor/ivacaftor; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before elexacaftor/tezacaftor/ivacaftor: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• eliglustat
Orgovyx (relugolix)

+

eliglustat

1 interaction

Avoid/Use Alternative

relugolix + eliglustat

PROSTATE CANCER: may hold relugolix if eliglustat tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before eliglustat; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before eliglustat: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• enasidenib
Orgovyx (relugolix)

+

enasidenib

1 interaction

Avoid/Use Alternative

relugolix + enasidenib

PROSTATE CANCER: may hold relugolix if enasidenib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before enasidenib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before enasidenib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• encorafenib
Orgovyx (relugolix)

+

encorafenib

1 interaction

Avoid/Use Alternative

relugolix + encorafenib

FIBROID-ASSOC. BLEEDING: if also combined w/ P-gp inducer, avoid combo; otherwise, caution advised; PROSTATE CANCER: if also combined w/ P-gp inducer, use alternative or incr. relugolix maint. dose to 240 mg/day; otherwise, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. relugolix levels, efficacy (additive effects, androgen deprivation may prolong QT; hepatic metabolism induced)

• entrectinib
Orgovyx (relugolix)

+

entrectinib

1 interaction

Avoid/Use Alternative

relugolix + entrectinib

PROSTATE CANCER: may hold relugolix if entrectinib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before entrectinib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before entrectinib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• ephedra
Orgovyx (relugolix)

+

ephedra

1 interaction

Avoid/Use Alternative

relugolix + ephedra

avoid combo if prostate cancer use: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• erdafitinib
Orgovyx (relugolix)

+

erdafitinib

1 interaction

Avoid/Use Alternative

relugolix + erdafitinib

PROSTATE CANCER: may hold relugolix if erdafitinib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and separate admin. by at least 6h; FIBROID-ASSOC. BLEEDING: use alternative or separate admin. by at least 6h: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport possibly inhibited)

• eribulin
Orgovyx (relugolix)

+

eribulin

1 interaction

Avoid/Use Alternative

relugolix + eribulin

if prostate cancer use, use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• erythromycin
Orgovyx (relugolix)

+

erythromycin

1 interaction

Avoid/Use Alternative

relugolix + erythromycin

PROSTATE CANCER, ORAL ERYTHROMYCIN: may hold relugolix if erythromycin tx up to 2wk; otherwise, use alternative or admin. relugolix at least 6h before erythromycin; monitor ECG, electrolytes; PROSTATE CANCER, IV ERYTHROMYCIN: monitor ECG, electrolytes; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before oral erythromycin: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited; additive effects, androgen deprivation may prolong QT)

• estetrol (contraceptive)
Orgovyx (relugolix)

+

estetrol (contraceptive)

1 interaction

Avoid/Use Alternative

relugolix + estetrol (contraceptive)

use alternative non-hormonal contraception during and x1wk after relugolix D/C: combo may decr. relugolix efficacy (antagonistic effects)

• estradiol (contraceptive)
Orgovyx (relugolix)

+

estradiol (contraceptive)

1 interaction

Avoid/Use Alternative

relugolix + estradiol (contraceptive)

use alternative non-hormonal contraception during and x1wk after relugolix D/C: combo may decr. relugolix efficacy (antagonistic effects)

• ethinyl estradiol (contraceptive)
Orgovyx (relugolix)

+

ethinyl estradiol (contraceptive)

1 interaction

Avoid/Use Alternative

relugolix + ethinyl estradiol (contraceptive)

use alternative non-hormonal contraception during and x1wk after relugolix D/C: combo may decr. relugolix efficacy (antagonistic effects)

• etravirine
Orgovyx (relugolix)

+

etravirine

1 interaction

Avoid/Use Alternative

relugolix + etravirine

consider alternative: combo may incr. or decr. relugolix levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (gut P-gp-mediated transport inhibited, hepatic metabolism induced)

• felodipine
Orgovyx (relugolix)

+

felodipine

1 interaction

Avoid/Use Alternative

relugolix + felodipine

PROSTATE CANCER: may hold relugolix if felodipine tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before felodipine; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before felodipine: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• fexinidazole
Orgovyx (relugolix)

+

fexinidazole

1 interaction

Avoid/Use Alternative

relugolix + fexinidazole

if prostate cancer use, if possible, do not initiate fexinidazole until 5 half-lives after relugolix D/C; use alternative or monitor ECG, electrolytes during and x7 days after fexinidazole tx: combo may decr. relugolix levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

• flibanserin
Orgovyx (relugolix)

+

flibanserin

1 interaction

Avoid/Use Alternative

relugolix + flibanserin

PROSTATE CANCER: may hold relugolix if flibanserin tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before flibanserin; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before flibanserin: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• fluvoxamine
Orgovyx (relugolix)

+

fluvoxamine

1 interaction

Avoid/Use Alternative

relugolix + fluvoxamine

PROSTATE CANCER: may hold relugolix if fluvoxamine tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before fluvoxamine; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before fluvoxamine: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• fosfomycin injection
Orgovyx (relugolix)

+

fosfomycin injection

1 interaction

Avoid/Use Alternative

relugolix + fosfomycin injection

if prostate cancer use, use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fosphenytoin
Orgovyx (relugolix)

+

fosphenytoin

1 interaction

Avoid/Use Alternative

relugolix + fosphenytoin

FIBROID-ASSOC. BLEEDING: avoid combo; PROSTATE CANCER: use alternative or incr. relugolix maint. dose to 240 mg/day: combo may decr. relugolix levels, efficacy (hepatic metabolism induced, P-gp-mediated transport induced)

• fostamatinib
Orgovyx (relugolix)

+

fostamatinib

1 interaction

Avoid/Use Alternative

relugolix + fostamatinib

PROSTATE CANCER: may hold relugolix if fostamatinib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before fostamatinib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before fostamatinib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• gilteritinib
Orgovyx (relugolix)

+

gilteritinib

1 interaction

Avoid/Use Alternative

relugolix + gilteritinib

PROSTATE CANCER: may hold relugolix if gilteritinib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before gilteritinib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before gilteritinib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport possibly inhibited; additive effects, androgen deprivation may prolong QT)

• ginkgo
Orgovyx (relugolix)

+

ginkgo

1 interaction

Avoid/Use Alternative

relugolix + ginkgo

PROSTATE CANCER: may hold relugolix if ginkgo tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before ginkgo; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before ginkgo: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• glecaprevir
Orgovyx (relugolix)

+

glecaprevir

1 interaction

Avoid/Use Alternative

relugolix + glecaprevir

PROSTATE CANCER: may hold relugolix if glecaprevir tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before glecaprevir; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before glecaprevir: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• goserelin
Orgovyx (relugolix)

+

goserelin

1 interaction

Avoid/Use Alternative

relugolix + goserelin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects (additive effects, duplicate GnRH modulation tx)

• histrelin
Orgovyx (relugolix)

+

histrelin

1 interaction

Avoid/Use Alternative

relugolix + histrelin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects (additive effects, duplicate GnRH modulation tx)

• hydroxychloroquine
Orgovyx (relugolix)

+

hydroxychloroquine

1 interaction

Avoid/Use Alternative

relugolix + hydroxychloroquine

if prostate cancer use, use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• ibrutinib
Orgovyx (relugolix)

+

ibrutinib

1 interaction

Avoid/Use Alternative

relugolix + ibrutinib

PROSTATE CANCER: may hold relugolix if ibrutinib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before ibrutinib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before ibrutinib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• imlunestrant
Orgovyx (relugolix)

+

imlunestrant

1 interaction

Avoid/Use Alternative

relugolix + imlunestrant

PROSTATE CANCER: may hold relugolix if imlunestrant tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before imlunestrant; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before [IN]: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• indomethacin
Orgovyx (relugolix)

+

indomethacin

1 interaction

Avoid/Use Alternative

relugolix + indomethacin

PROSTATE CANCER: may hold relugolix if oral indomethacin tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before oral indomethacin; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before oral indomethacin: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• isavuconazonium
Orgovyx (relugolix)

+

isavuconazonium

1 interaction

Avoid/Use Alternative

relugolix + isavuconazonium

PROSTATE CANCER: may hold relugolix if oral isavuconazonium tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before oral isavuconazonium; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before oral isavuconazonium: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• istradefylline
Orgovyx (relugolix)

+

istradefylline

1 interaction

Avoid/Use Alternative

relugolix + istradefylline

PROSTATE CANCER: may hold relugolix if istradefylline tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before istradefylline; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before istradefylline: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• itraconazole
Orgovyx (relugolix)

+

itraconazole

1 interaction

Avoid/Use Alternative

relugolix + itraconazole

PROSTATE CANCER: may hold relugolix if itraconazole tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before itraconazole; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before itraconazole: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• ivacaftor
Orgovyx (relugolix)

+

ivacaftor

1 interaction

Avoid/Use Alternative

relugolix + ivacaftor

PROSTATE CANCER: may hold relugolix if ivacaftor tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before ivacaftor; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before ivacaftor: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• ivosidenib
Orgovyx (relugolix)

+

ivosidenib

1 interaction

Avoid/Use Alternative

relugolix + ivosidenib

FIBROID-ASSOC. BLEEDING: if also combined w/ P-gp inducer, avoid combo; otherwise, caution advised; PROSTATE CANCER: monitor ECG, electrolytes; if also combined w/ P-gp inducer, use alternative or incr. relugolix maint. dose to 240 mg/day: combo may decr. relugolix levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects, additive effects, androgen deprivation may prolong QT)

• ketoconazole
Orgovyx (relugolix)

+

ketoconazole

1 interaction

Avoid/Use Alternative

relugolix + ketoconazole

PROSTATE CANCER: may hold relugolix if ketoconazole tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before ketoconazole; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before ketoconazole: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• lapatinib
Orgovyx (relugolix)

+

lapatinib

1 interaction

Avoid/Use Alternative

relugolix + lapatinib

PROSTATE CANCER: may hold relugolix if lapatinib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before lapatinib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before lapatinib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• ledipasvir
Orgovyx (relugolix)

+

ledipasvir

1 interaction

Avoid/Use Alternative

relugolix + ledipasvir

PROSTATE CANCER: may hold relugolix if ledipasvir tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before ledipasvir; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before ledipasvir: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• lefamulin
Orgovyx (relugolix)

+

lefamulin

1 interaction

Avoid/Use Alternative

relugolix + lefamulin

if prostate cancer use, use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• lenacapavir
Orgovyx (relugolix)

+

lenacapavir

1 interaction

Avoid/Use Alternative

relugolix + lenacapavir

PROSTATE CANCER: use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before oral lenacapavir tx; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before oral lenacapavir tx: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• leuprolide
Orgovyx (relugolix)

+

leuprolide

1 interaction

Avoid/Use Alternative

relugolix + leuprolide

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects (additive effects, duplicate GnRH modulation tx)

• levacetylleucine
Orgovyx (relugolix)

+

levacetylleucine

1 interaction

Avoid/Use Alternative

relugolix + levacetylleucine

PROSTATE CANCER: may hold relugolix if levacetylleucine tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before levacetylleucine; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before levacetylleucine: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport possibly inhibited)

• levoketoconazole
Orgovyx (relugolix)

+

levoketoconazole

1 interaction

Avoid/Use Alternative

relugolix + levoketoconazole

PROSTATE CANCER: may hold relugolix if levoketoconazole tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before levoketoconazole; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before levoketoconazole: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited; additive effects, androgen deprivation may prolong QT)

• lomitapide
Orgovyx (relugolix)

+

lomitapide

1 interaction

Avoid/Use Alternative

relugolix + lomitapide

PROSTATE CANCER: may hold relugolix if lomitapide tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before lomitapide; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before lomitapide: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport possibly inhibited)

• lonafarnib
Orgovyx (relugolix)

+

lonafarnib

1 interaction

Avoid/Use Alternative

relugolix + lonafarnib

PROSTATE CANCER: may hold relugolix if lonafarnib tx up to 2wk; otherwise, use alternative or monitor HR, ECG, electrolytes and admin. relugolix at least 6h before lonafarnib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before lonafarnib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited; additive effects, androgen deprivation may prolong QT)

• lopinavir/ritonavir
Orgovyx (relugolix)

+

lopinavir/ ritonavir

1 interaction

Avoid/Use Alternative

relugolix + lopinavir/ ritonavir

consider alternative: combo may incr. or decr. relugolix levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (gut P-gp-mediated transport inhibited, hepatic metabolism induced)

• lorlatinib
Orgovyx (relugolix)

+

lorlatinib

1 interaction

Avoid/Use Alternative

relugolix + lorlatinib

FIBROID-ASSOC. BLEEDING: if also combined w/ strong CYP3A4 inducer, avoid combo; otherwise, caution advised; PROSTATE CANCER: if also combined w/ strong CYP3A4 inducer, use alternative or incr. relugolix maint. dose to 240 mg/day; otherwise, caution advised: combo may decr. relugolix levels, efficacy (hepatic metabolism induced, P-gp-mediated transport induced)

• lumacaftor/ivacaftor
Orgovyx (relugolix)

+

lumacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

relugolix + lumacaftor/ ivacaftor

consider alternative: combo may incr. or decr. relugolix levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (gut P-gp-mediated transport inhibited, hepatic metabolism induced, P-gp-mediated transport possibly induced)

• maribavir
Orgovyx (relugolix)

+

maribavir

1 interaction

Avoid/Use Alternative

relugolix + maribavir

PROSTATE CANCER: may hold relugolix if maribavir tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before maribavir; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before maribavir: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• mavorixafor
Orgovyx (relugolix)

+

mavorixafor

1 interaction

Avoid/Use Alternative

relugolix + mavorixafor

PROSTATE CANCER: may hold relugolix if mavorixafor tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before mavorixafor; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before mavorixafor: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• mifepristone
Orgovyx (relugolix)

+

mifepristone

1 interaction

Avoid/Use Alternative

relugolix + mifepristone

PROSTATE CANCER: may hold relugolix if mifepristone tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before mifepristone; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before mifepristone: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• milk thistle
Orgovyx (relugolix)

+

milk thistle

1 interaction

Avoid/Use Alternative

relugolix + milk thistle

PROSTATE CANCER: may hold relugolix if oral milk thistle tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before oral milk thistle; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before oral milk thistle: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• mirabegron
Orgovyx (relugolix)

+

mirabegron

1 interaction

Avoid/Use Alternative

relugolix + mirabegron

PROSTATE CANCER: may hold relugolix if mirabegron tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before mirabegron; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before mirabegron: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• mitapivat
Orgovyx (relugolix)

+

mitapivat

1 interaction

Avoid/Use Alternative

relugolix + mitapivat

PROSTATE CANCER: may hold relugolix if mitapivat tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before mitapivat; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before mitapivat: combo may incr. or decr. relugolix levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (gut P-gp-mediated transport possibly inhibited, hepatic metabolism induced)

• mitotane
Orgovyx (relugolix)

+

mitotane

1 interaction

Avoid/Use Alternative

relugolix + mitotane

FIBROID-ASSOC. BLEEDING: if also combined w/ P-gp inducer, avoid combo; otherwise, caution advised; PROSTATE CANCER: if also combined w/ P-gp inducer, use alternative or incr. relugolix maint. dose to 240 mg/day; otherwise, caution advised: combo may decr. relugolix levels, efficacy (hepatic metabolism induced)

• mobocertinib
Orgovyx (relugolix)

+

mobocertinib

1 interaction

Avoid/Use Alternative

relugolix + mobocertinib

if prostate cancer use, use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• naproxen
Orgovyx (relugolix)

+

naproxen

1 interaction

Avoid/Use Alternative

relugolix + naproxen

PROSTATE CANCER: may hold relugolix if naproxen tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before naproxen; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before naproxen: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• nefazodone
Orgovyx (relugolix)

+

nefazodone

1 interaction

Avoid/Use Alternative

relugolix + nefazodone

PROSTATE CANCER: may hold relugolix if nefazodone tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before nefazodone; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before nefazodone: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• nelfinavir
Orgovyx (relugolix)

+

nelfinavir

1 interaction

Avoid/Use Alternative

relugolix + nelfinavir

PROSTATE CANCER: may hold relugolix if nelfinavir tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before nelfinavir; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before nelfinavir: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• neratinib
Orgovyx (relugolix)

+

neratinib

1 interaction

Avoid/Use Alternative

relugolix + neratinib

PROSTATE CANCER: may hold relugolix if neratinib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before neratinib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before neratinib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• nifedipine
Orgovyx (relugolix)

+

nifedipine

1 interaction

Avoid/Use Alternative

relugolix + nifedipine

PROSTATE CANCER: may hold relugolix if nifedipine tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before nifedipine; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before nifedipine: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• osimertinib
Orgovyx (relugolix)

+

osimertinib

1 interaction

Avoid/Use Alternative

relugolix + osimertinib

PROSTATE CANCER: may hold relugolix if osimertinib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before osimertinib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before osimertinib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited; additive effects, androgen deprivation may prolong QT)

• pacritinib
Orgovyx (relugolix)

+

pacritinib

1 interaction

Avoid/Use Alternative

relugolix + pacritinib

consider alternative: combo may incr. or decr. relugolix levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (hepatic metabolism induced, gut P-gp-mediated transport inhibited, additive effects, androgen deprivation may prolong QT)

• paroxetine
Orgovyx (relugolix)

+

paroxetine

1 interaction

Avoid/Use Alternative

relugolix + paroxetine

PROSTATE CANCER: may hold relugolix if paroxetine tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before paroxetine; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before paroxetine: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• pentobarbital
Orgovyx (relugolix)

+

pentobarbital

1 interaction

Avoid/Use Alternative

relugolix + pentobarbital

FIBROID-ASSOC. BLEEDING: if also combined w/ P-gp inducer, avoid combo; otherwise, caution advised; PROSTATE CANCER: if also combined w/ P-gp inducer, use alternative or incr. relugolix maint. dose to 240 mg/day; otherwise, caution advised: combo may decr. relugolix levels, efficacy (hepatic metabolism induced)

• phenobarbital
Orgovyx (relugolix)

+

phenobarbital

1 interaction

Avoid/Use Alternative

relugolix + phenobarbital

FIBROID-ASSOC. BLEEDING: avoid combo; PROSTATE CANCER: use alternative or incr. relugolix maint. dose to 240 mg/day: combo may decr. relugolix levels, efficacy (hepatic metabolism induced, P-gp-mediated transport possibly induced)

• phenytoin
Orgovyx (relugolix)

+

phenytoin

1 interaction

Avoid/Use Alternative

relugolix + phenytoin

FIBROID-ASSOC. BLEEDING: avoid combo; PROSTATE CANCER: use alternative or incr. relugolix maint. dose to 240 mg/day: combo may decr. relugolix levels, efficacy (hepatic metabolism induced, P-gp-mediated transport induced)

• pibrentasvir
Orgovyx (relugolix)

+

pibrentasvir

1 interaction

Avoid/Use Alternative

relugolix + pibrentasvir

PROSTATE CANCER: may hold relugolix if pibrentasvir tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before pibrentasvir; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before pibrentasvir: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• pirtobrutinib
Orgovyx (relugolix)

+

pirtobrutinib

1 interaction

Avoid/Use Alternative

relugolix + pirtobrutinib

PROSTATE CANCER: may hold relugolix if pirtobrutinib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before pirtobrutinib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before pirtobrutinib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• ponatinib
Orgovyx (relugolix)

+

ponatinib

1 interaction

Avoid/Use Alternative

relugolix + ponatinib

PROSTATE CANCER: may hold relugolix if ponatinib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before ponatinib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before ponatinib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport possibly inhibited)

• posaconazole
Orgovyx (relugolix)

+

posaconazole

1 interaction

Avoid/Use Alternative

relugolix + posaconazole

PROSTATE CANCER: may hold relugolix if oral posaconazole tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before oral posaconazole; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before oral posaconazole: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• primaquine
Orgovyx (relugolix)

+

primaquine

1 interaction

Avoid/Use Alternative

relugolix + primaquine

PROSTATE CANCER: may hold relugolix if primaquine use up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and give relugolix at least 6h before primaquine; FIBROID-ASSOC. BLEEDING: use alternative or give relugolix at least 6h before primaquine: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport possibly inhibited)

• primidone
Orgovyx (relugolix)

+

primidone

1 interaction

Avoid/Use Alternative

relugolix + primidone

FIBROID-ASSOC. BLEEDING: avoid combo; PROSTATE CANCER: use alternative or incr. relugolix maint. dose to 240 mg/day: combo may decr. relugolix levels, efficacy (hepatic metabolism induced, P-gp-mediated transport possibly induced)

• propafenone
Orgovyx (relugolix)

+

propafenone

1 interaction

Avoid/Use Alternative

relugolix + propafenone

PROSTATE CANCER: may hold relugolix if propafenone tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before propafenone; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before propafenone: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited; additive effects, androgen deprivation may prolong QT)

• quercetin
Orgovyx (relugolix)

+

quercetin

1 interaction

Avoid/Use Alternative

relugolix + quercetin

PROSTATE CANCER: may hold relugolix if quercetin tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before quercetin; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before quercetin: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• quinidine (antiarrhythmic)
Orgovyx (relugolix)

+

quinidine (antiarrhythmic)

1 interaction

Avoid/Use Alternative

relugolix + quinidine (antiarrhythmic)

PROSTATE CANCER: may hold relugolix if quinidine tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before quinidine; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before quinidine: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited; additive effects, androgen deprivation may prolong QT)

• quinidine (CYP2D6 inhibitor)
Orgovyx (relugolix)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Avoid/Use Alternative

relugolix + quinidine (CYP2D6 inhibitor)

PROSTATE CANCER: may hold relugolix if quinidine tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before quinidine; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before quinidine: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited; additive effects, androgen deprivation may prolong QT)

• quinine
Orgovyx (relugolix)

+

quinine

1 interaction

Avoid/Use Alternative

relugolix + quinine

PROSTATE CANCER: may hold relugolix if quinine tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before quinine; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before quinine: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited; additive effects, androgen deprivation may prolong QT)

• quizartinib
Orgovyx (relugolix)

+

quizartinib

1 interaction

Avoid/Use Alternative

relugolix + quizartinib

use alternative or monitor ECG, electrolytes if prostate cancer use: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• ranolazine
Orgovyx (relugolix)

+

ranolazine

1 interaction

Avoid/Use Alternative

relugolix + ranolazine

PROSTATE CANCER: may hold relugolix if ranolazine tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before ranolazine; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before ranolazine: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• remibrutinib
Orgovyx (relugolix)

+

remibrutinib

1 interaction

Avoid/Use Alternative

relugolix + remibrutinib

PROSTATE CANCER: may hold relugolix if remibrutinib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before remibrutinib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before remibrutinib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• rifabutin
Orgovyx (relugolix)

+

rifabutin

1 interaction

Avoid/Use Alternative

relugolix + rifabutin

FIBROID-ASSOC. BLEEDING: avoid combo; PROSTATE CANCER: use alternative or incr. relugolix maint. dose to 240 mg/day: combo may decr. relugolix levels, efficacy (hepatic metabolism induced, P-gp-mediated transport possibly induced)

• rifampin
Orgovyx (relugolix)

+

rifampin

1 interaction

Avoid/Use Alternative

relugolix + rifampin

FIBROID-ASSOC. BLEEDING: avoid combo; PROSTATE CANCER: use alternative or incr. relugolix maint. dose to 240 mg/day: combo may decr. relugolix levels, efficacy (hepatic metabolism induced, P-gp-mediated transport induced)

• rifapentine
Orgovyx (relugolix)

+

rifapentine

1 interaction

Avoid/Use Alternative

relugolix + rifapentine

FIBROID-ASSOC. BLEEDING: if also combined w/ strong CYP3A4 inducer, avoid combo; otherwise, caution advised; PROSTATE CANCER: if also combined w/ strong CYP3A4 inducer, use alternative or incr. relugolix maint. dose to 240 mg/day; otherwise, caution advised: combo may decr. relugolix levels, efficacy (hepatic metabolism induced, P-gp-mediated transport possibly induced)

• rilzabrutinib
Orgovyx (relugolix)

+

rilzabrutinib

1 interaction

Avoid/Use Alternative

relugolix + rilzabrutinib

PROSTATE CANCER: may hold relugolix if rilzabrutinib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before rilzabrutinib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before rilzabrutinib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport possibly inhibited)

• ritonavir
Orgovyx (relugolix)

+

ritonavir

1 interaction

Avoid/Use Alternative

relugolix + ritonavir

PROSTATE CANCER: may hold relugolix if ritonavir tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before ritonavir; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before ritonavir: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• rolapitant
Orgovyx (relugolix)

+

rolapitant

1 interaction

Avoid/Use Alternative

relugolix + rolapitant

PROSTATE CANCER: may hold relugolix if rolapitant tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before rolapitant; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before rolapitant: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• rucaparib
Orgovyx (relugolix)

+

rucaparib

1 interaction

Avoid/Use Alternative

relugolix + rucaparib

PROSTATE CANCER: may hold relugolix if rucaparib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before rucaparib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before rucaparib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited; additive effects, androgen deprivation may prolong QT)

• sarecycline
Orgovyx (relugolix)

+

sarecycline

1 interaction

Avoid/Use Alternative

relugolix + sarecycline

PROSTATE CANCER: may hold relugolix if sarecycline tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before sarecycline; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before sarecycline: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• selpercatinib
Orgovyx (relugolix)

+

selpercatinib

1 interaction

Avoid/Use Alternative

relugolix + selpercatinib

PROSTATE CANCER: may hold relugolix if selpercatinib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before selpercatinib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before selpercatinib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited; additive effects, androgen deprivation may prolong QT)

• sevabertinib
Orgovyx (relugolix)

+

sevabertinib

1 interaction

Avoid/Use Alternative

relugolix + sevabertinib

PROSTATE CANCER: may hold relugolix if sevabertinib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before sevabertinib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before sevabertinib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited)

• simvastatin
Orgovyx (relugolix)

+

simvastatin

1 interaction

Avoid/Use Alternative

relugolix + simvastatin

PROSTATE CANCER: may hold relugolix if simvastatin tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before simvastatin; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before simvastatin: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• sorafenib
Orgovyx (relugolix)

+

sorafenib

1 interaction

Avoid/Use Alternative

relugolix + sorafenib

PROSTATE CANCER: may hold relugolix if sorafenib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before sorafenib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before sorafenib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport possibly inhibited)

• sotagliflozin
Orgovyx (relugolix)

+

sotagliflozin

1 interaction

Avoid/Use Alternative

relugolix + sotagliflozin

PROSTATE CANCER: may hold relugolix if sotagliflozin tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before sotagliflozin; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before sotagliflozin: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• sotalol
Orgovyx (relugolix)

+

sotalol

1 interaction

Avoid/Use Alternative

relugolix + sotalol

if prostate cancer use, use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• sotorasib
Orgovyx (relugolix)

+

sotorasib

1 interaction

Avoid/Use Alternative

relugolix + sotorasib

PROSTATE CANCER: may hold relugolix if sotorasib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before sotorasib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before sotorasib: combo may incr. or decr. relugolix levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (gut P-gp-mediated transport inhibited, hepatic metabolism induced)

• sparsentan
Orgovyx (relugolix)

+

sparsentan

1 interaction

Avoid/Use Alternative

relugolix + sparsentan

PROSTATE CANCER: may hold relugolix if sparsentan tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before sparsentan; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before sparsentan: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport possibly inhibited)

• St. John's wort
Orgovyx (relugolix)

+

St. John's wort

1 interaction

Avoid/Use Alternative

relugolix + St. John's wort

FIBROID-ASSOC. BLEEDING: avoid combo; PROSTATE CANCER: use alternative or incr. relugolix maint. dose to 240 mg/day: combo may decr. relugolix levels, efficacy (hepatic metabolism induced, P-gp-mediated transport induced)

• stiripentol
Orgovyx (relugolix)

+

stiripentol

1 interaction

Avoid/Use Alternative

relugolix + stiripentol

PROSTATE CANCER: may hold relugolix if stiripentol tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before stiripentol; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before stiripentol: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• sunvozertinib
Orgovyx (relugolix)

+

sunvozertinib

1 interaction

Avoid/Use Alternative

relugolix + sunvozertinib

PROSTATE CANCER: may hold relugolix if sunvozertinib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before sunvozertinib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before sunvozertinib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• suvorexant
Orgovyx (relugolix)

+

suvorexant

1 interaction

Avoid/Use Alternative

relugolix + suvorexant

PROSTATE CANCER: may hold relugolix if suvorexant tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before suvorexant; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before suvorexant: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• tacrolimus
Orgovyx (relugolix)

+

tacrolimus

1 interaction

Avoid/Use Alternative

relugolix + tacrolimus

PROSTATE CANCER: may hold relugolix if oral tacrolimus tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before oral tacrolimus; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before oral tacrolimus: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport possibly inhibited)

• taletrectinib
Orgovyx (relugolix)

+

taletrectinib

1 interaction

Avoid/Use Alternative

relugolix + taletrectinib

use alternative or monitor ECG, electrolytes if prostate cancer use: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• telmisartan
Orgovyx (relugolix)

+

telmisartan

1 interaction

Avoid/Use Alternative

relugolix + telmisartan

PROSTATE CANCER: may hold relugolix if telmisartan tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before telmisartan; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before telmisartan: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• tepotinib
Orgovyx (relugolix)

+

tepotinib

1 interaction

Avoid/Use Alternative

relugolix + tepotinib

PROSTATE CANCER: may hold relugolix if tepotinib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before tepotinib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before tepotinib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• tezacaftor/ivacaftor
Orgovyx (relugolix)

+

tezacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

relugolix + tezacaftor/ ivacaftor

PROSTATE CANCER: may hold relugolix if tezacaftor/ivacaftor tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before tezacaftor/ivacaftor; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before tezacaftor/ivacaftor: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• ticagrelor
Orgovyx (relugolix)

+

ticagrelor

1 interaction

Avoid/Use Alternative

relugolix + ticagrelor

PROSTATE CANCER: may hold relugolix if ticagrelor tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before ticagrelor; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before ticagrelor: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• tipranavir
Orgovyx (relugolix)

+

tipranavir

1 interaction

Avoid/Use Alternative

relugolix + tipranavir

consider alternative: combo may incr. or decr. relugolix levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (gut P-gp-mediated transport inhibited, P-gp-mediated transport induced)

• tolvaptan
Orgovyx (relugolix)

+

tolvaptan

1 interaction

Avoid/Use Alternative

relugolix + tolvaptan

PROSTATE CANCER: may hold relugolix if tolvaptan tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before tolvaptan; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before tolvaptan: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• toremifene
Orgovyx (relugolix)

+

toremifene

1 interaction

Avoid/Use Alternative

relugolix + toremifene

if prostate cancer use, use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• trazodone
Orgovyx (relugolix)

+

trazodone

1 interaction

Avoid/Use Alternative

relugolix + trazodone

PROSTATE CANCER: may hold relugolix if trazodone tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before trazodone; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before trazodone: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• trimethoprim
Orgovyx (relugolix)

+

trimethoprim

1 interaction

Avoid/Use Alternative

relugolix + trimethoprim

PROSTATE CANCER: may hold relugolix if oral trimethoprim tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before oral trimethoprim; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before oral trimethoprim: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• triptorelin
Orgovyx (relugolix)

+

triptorelin

1 interaction

Avoid/Use Alternative

relugolix + triptorelin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects (additive effects, duplicate GnRH modulation tx)

• trofinetide
Orgovyx (relugolix)

+

trofinetide

1 interaction

Avoid/Use Alternative

relugolix + trofinetide

PROSTATE CANCER: may hold relugolix if trofinetide tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before trofinetide; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before trofinetide: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• tucatinib
Orgovyx (relugolix)

+

tucatinib

1 interaction

Avoid/Use Alternative

relugolix + tucatinib

PROSTATE CANCER: may hold relugolix if tucatinib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before tucatinib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before tucatinib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• turmeric
Orgovyx (relugolix)

+

turmeric

1 interaction

Avoid/Use Alternative

relugolix + turmeric

avoid combo w/ oral turmeric: combo may incr. or decr. relugolix levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (P-gp-mediated transport altered)

• uridine triacetate
Orgovyx (relugolix)

+

uridine triacetate

1 interaction

Avoid/Use Alternative

relugolix + uridine triacetate

PROSTATE CANCER: may hold relugolix if uridine triacetate tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before uridine triacetate; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before uridine triacetate: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport possibly inhibited)

• valbenazine
Orgovyx (relugolix)

+

valbenazine

1 interaction

Avoid/Use Alternative

relugolix + valbenazine

PROSTATE CANCER: may hold relugolix if valbenazine tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before valbenazine; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before valbenazine: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• vandetanib
Orgovyx (relugolix)

+

vandetanib

1 interaction

Avoid/Use Alternative

relugolix + vandetanib

PROSTATE CANCER: may hold relugolix if vandetanib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before vandetanib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before vandetanib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited; additive effects, androgen deprivation may prolong QT)

• vanzacaftor/tezacaftor/deutivacaftor
Orgovyx (relugolix)

+

vanzacaftor/ tezacaftor/ deutivacaftor

1 interaction

Avoid/Use Alternative

relugolix + vanzacaftor/ tezacaftor/ deutivacaftor

PROSTATE CANCER: may hold relugolix if vanzacaftor/tezacaftor/deutivacaftor tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before vanzacaftor/tezacaftor/deutivacaftor; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before vanzacaftor/tezacaftor/deutivacaftor: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport possibly inhibited)

• velpatasvir
Orgovyx (relugolix)

+

velpatasvir

1 interaction

Avoid/Use Alternative

relugolix + velpatasvir

PROSTATE CANCER: may hold relugolix if velpatasvir tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before velpatasvir; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before velpatasvir: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• vemurafenib
Orgovyx (relugolix)

+

vemurafenib

1 interaction

Avoid/Use Alternative

relugolix + vemurafenib

PROSTATE CANCER: may hold relugolix if vemurafenib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before vemurafenib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before vemurafenib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited; additive effects, androgen deprivation may prolong QT)

• venetoclax
Orgovyx (relugolix)

+

venetoclax

1 interaction

Avoid/Use Alternative

relugolix + venetoclax

PROSTATE CANCER: may hold relugolix if venetoclax tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before venetoclax; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before venetoclax: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• verapamil
Orgovyx (relugolix)

+

verapamil

1 interaction

Avoid/Use Alternative

relugolix + verapamil

PROSTATE CANCER: may hold relugolix if oral verapamil tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before oral verapamil; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before oral verapamil: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• voclosporin
Orgovyx (relugolix)

+

voclosporin

1 interaction

Avoid/Use Alternative

relugolix + voclosporin

PROSTATE CANCER: may hold relugolix if voclosporin tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before voclosporin; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before voclosporin: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• voxilaprevir
Orgovyx (relugolix)

+

voxilaprevir

1 interaction

Avoid/Use Alternative

relugolix + voxilaprevir

PROSTATE CANCER: may hold relugolix if voxilaprevir tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before voxilaprevir; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before voxilaprevir: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• xanomeline
Orgovyx (relugolix)

+

xanomeline

1 interaction

Avoid/Use Alternative

relugolix + xanomeline

PROSTATE CANCER: may hold relugolix if xanomeline tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before xanomeline; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before xanomeline: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport possibly inhibited)

• ziprasidone
Orgovyx (relugolix)

+

ziprasidone

1 interaction

Avoid/Use Alternative

relugolix + ziprasidone

if prostate cancer use, use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• zonisamide
Orgovyx (relugolix)

+

zonisamide

1 interaction

Avoid/Use Alternative

relugolix + zonisamide

PROSTATE CANCER: may hold relugolix if zonisamide tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before zonisamide; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before zonisamide: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport possibly inhibited)

Monitor/Modify Tx

• anagrelide
Orgovyx (relugolix)

+

anagrelide

1 interaction

Monitor/Modify Tx

relugolix + anagrelide

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• apomorphine
Orgovyx (relugolix)

+

apomorphine

1 interaction

Monitor/Modify Tx

relugolix + apomorphine

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• artemether/lumefantrine
Orgovyx (relugolix)

+

artemether/ lumefantrine

1 interaction

Monitor/Modify Tx

relugolix + artemether/ lumefantrine

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• asenapine
Orgovyx (relugolix)

+

asenapine

1 interaction

Monitor/Modify Tx

relugolix + asenapine

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• cabozantinib
Orgovyx (relugolix)

+

cabozantinib

1 interaction

Monitor/Modify Tx

relugolix + cabozantinib

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• ceritinib
Orgovyx (relugolix)

+

ceritinib

1 interaction

Monitor/Modify Tx

relugolix + ceritinib

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• chloroquine
Orgovyx (relugolix)

+

chloroquine

1 interaction

Monitor/Modify Tx

relugolix + chloroquine

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• citalopram
Orgovyx (relugolix)

+

citalopram

1 interaction

Monitor/Modify Tx

relugolix + citalopram

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• clofazimine
Orgovyx (relugolix)

+

clofazimine

1 interaction

Monitor/Modify Tx

relugolix + clofazimine

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• degarelix
Orgovyx (relugolix)

+

degarelix

1 interaction

Monitor/Modify Tx

relugolix + degarelix

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• desflurane
Orgovyx (relugolix)

+

desflurane

1 interaction

Monitor/Modify Tx

relugolix + desflurane

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• desipramine
Orgovyx (relugolix)

+

desipramine

1 interaction

Monitor/Modify Tx

relugolix + desipramine

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• dexmedetomidine
Orgovyx (relugolix)

+

dexmedetomidine

1 interaction

Monitor/Modify Tx

relugolix + dexmedetomidine

if prostate cancer use, monitor HR, ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• dexmedetomidine injection
Orgovyx (relugolix)

+

dexmedetomidine injection

1 interaction

Monitor/Modify Tx

relugolix + dexmedetomidine injection

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• disopyramide
Orgovyx (relugolix)

+

disopyramide

1 interaction

Monitor/Modify Tx

relugolix + disopyramide

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• dofetilide
Orgovyx (relugolix)

+

dofetilide

1 interaction

Monitor/Modify Tx

relugolix + dofetilide

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• donepezil
Orgovyx (relugolix)

+

donepezil

1 interaction

Monitor/Modify Tx

relugolix + donepezil

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• dordaviprone
Orgovyx (relugolix)

+

dordaviprone

1 interaction

Monitor/Modify Tx

relugolix + dordaviprone

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• droperidol
Orgovyx (relugolix)

+

droperidol

1 interaction

Monitor/Modify Tx

relugolix + droperidol

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• epirubicin
Orgovyx (relugolix)

+

epirubicin

1 interaction

Monitor/Modify Tx

relugolix + epirubicin

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• flecainide
Orgovyx (relugolix)

+

flecainide

1 interaction

Monitor/Modify Tx

relugolix + flecainide

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• fluorouracil
Orgovyx (relugolix)

+

fluorouracil

1 interaction

Monitor/Modify Tx

relugolix + fluorouracil

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• glasdegib
Orgovyx (relugolix)

+

glasdegib

1 interaction

Monitor/Modify Tx

relugolix + glasdegib

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• haloperidol
Orgovyx (relugolix)

+

haloperidol

1 interaction

Monitor/Modify Tx

relugolix + haloperidol

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• hydroxyzine
Orgovyx (relugolix)

+

hydroxyzine

1 interaction

Monitor/Modify Tx

relugolix + hydroxyzine

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• ibutilide
Orgovyx (relugolix)

+

ibutilide

1 interaction

Monitor/Modify Tx

relugolix + ibutilide

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• inotuzumab ozogamicin
Orgovyx (relugolix)

+

inotuzumab ozogamicin

1 interaction

Monitor/Modify Tx

relugolix + inotuzumab ozogamicin

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• isoflurane
Orgovyx (relugolix)

+

isoflurane

1 interaction

Monitor/Modify Tx

relugolix + isoflurane

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• levofloxacin
Orgovyx (relugolix)

+

levofloxacin

1 interaction

Monitor/Modify Tx

relugolix + levofloxacin

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• lofexidine
Orgovyx (relugolix)

+

lofexidine

1 interaction

Monitor/Modify Tx

relugolix + lofexidine

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• macimorelin
Orgovyx (relugolix)

+

macimorelin

1 interaction

Monitor/Modify Tx

relugolix + macimorelin

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• methadone
Orgovyx (relugolix)

+

methadone

1 interaction

Monitor/Modify Tx

relugolix + methadone

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• moxifloxacin
Orgovyx (relugolix)

+

moxifloxacin

1 interaction

Monitor/Modify Tx

relugolix + moxifloxacin

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• nilotinib
Orgovyx (relugolix)

+

nilotinib

1 interaction

Monitor/Modify Tx

relugolix + nilotinib

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• oliceridine
Orgovyx (relugolix)

+

oliceridine

1 interaction

Monitor/Modify Tx

relugolix + oliceridine

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• ondansetron
Orgovyx (relugolix)

+

ondansetron

1 interaction

Monitor/Modify Tx

relugolix + ondansetron

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• paliperidone
Orgovyx (relugolix)

+

paliperidone

1 interaction

Monitor/Modify Tx

relugolix + paliperidone

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• palonosetron
Orgovyx (relugolix)

+

palonosetron

1 interaction

Monitor/Modify Tx

relugolix + palonosetron

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• pasireotide
Orgovyx (relugolix)

+

pasireotide

1 interaction

Monitor/Modify Tx

relugolix + pasireotide

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• pentamidine
Orgovyx (relugolix)

+

pentamidine

1 interaction

Monitor/Modify Tx

relugolix + pentamidine

if prostate cancer use, monitor ECG, electrolytes; risk may be lower w/ nebulized pentamidine: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• pretomanid
Orgovyx (relugolix)

+

pretomanid

1 interaction

Monitor/Modify Tx

relugolix + pretomanid

PROSTATE CANCER: monitor ECG, electrolytes and admin. relugolix at least 6h before pretomanid; FIBROID-ASSOC. BLEEDING: admin. relugolix at least 6h before pretomanid: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport possibly inhibited)

• procainamide
Orgovyx (relugolix)

+

procainamide

1 interaction

Monitor/Modify Tx

relugolix + procainamide

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• revumenib
Orgovyx (relugolix)

+

revumenib

1 interaction

Monitor/Modify Tx

relugolix + revumenib

monitor ECG, electrolytes if prostate cancer use: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• ribociclib
Orgovyx (relugolix)

+

ribociclib

1 interaction

Monitor/Modify Tx

relugolix + ribociclib

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• romidepsin
Orgovyx (relugolix)

+

romidepsin

1 interaction

Monitor/Modify Tx

relugolix + romidepsin

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• sevoflurane
Orgovyx (relugolix)

+

sevoflurane

1 interaction

Monitor/Modify Tx

relugolix + sevoflurane

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• telavancin
Orgovyx (relugolix)

+

telavancin

1 interaction

Monitor/Modify Tx

relugolix + telavancin

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• tetrabenazine
Orgovyx (relugolix)

+

tetrabenazine

1 interaction

Monitor/Modify Tx

relugolix + tetrabenazine

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• tramadol
Orgovyx (relugolix)

+

tramadol

1 interaction

Monitor/Modify Tx

relugolix + tramadol

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• triclabendazole
Orgovyx (relugolix)

+

triclabendazole

1 interaction

Monitor/Modify Tx

relugolix + triclabendazole

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• trifluridine
Orgovyx (relugolix)

+

trifluridine

1 interaction

Monitor/Modify Tx

relugolix + trifluridine

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• vimseltinib
Orgovyx (relugolix)

+

vimseltinib

1 interaction

Monitor/Modify Tx

relugolix + vimseltinib

PROSTATE CANCER: use alternative or monitor ECG, electrolytes and separate admin. by at least 6h; FIBROID-ASSOC. BLEEDING: use alternative or separate admin. by at least 6h: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• ziftomenib
Orgovyx (relugolix)

+

ziftomenib

1 interaction

Monitor/Modify Tx

relugolix + ziftomenib

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

Caution Advised

• bosentan
Orgovyx (relugolix)

+

bosentan

1 interaction

Caution Advised

relugolix + bosentan

caution advised if also combined w/ P-gp inducer: combo may decr. relugolix levels, efficacy (hepatic metabolism induced)

• cenobamate
Orgovyx (relugolix)

+

cenobamate

1 interaction

Caution Advised

relugolix + cenobamate

caution advised if also combined w/ P-gp inducer: combo may decr. relugolix levels, efficacy (hepatic metabolism induced)

• dabrafenib
Orgovyx (relugolix)

+

dabrafenib

1 interaction

Caution Advised

relugolix + dabrafenib

caution advised if also combined w/ P-gp inducer: combo may decr. relugolix levels, efficacy (hepatic metabolism induced)

• estrogens, conjugated (hormone replacement)
Orgovyx (relugolix)

+

estrogens, conjugated (hormone replacement)

1 interaction

Caution Advised

relugolix + estrogens, conjugated (hormone replacement)

caution advised: combo may decr. relugolix efficacy (antagonistic effects)

• estrogens, esterified (hormone replacement)
Orgovyx (relugolix)

+

estrogens, esterified (hormone replacement)

1 interaction

Caution Advised

relugolix + estrogens, esterified (hormone replacement)

caution advised: combo may decr. relugolix efficacy (antagonistic effects)

• ethinyl estradiol (hormone replacement)
Orgovyx (relugolix)

+

ethinyl estradiol (hormone replacement)

1 interaction

Caution Advised

relugolix + ethinyl estradiol (hormone replacement)

caution advised: combo may decr. relugolix efficacy (antagonistic effects)

• mavacamten
Orgovyx (relugolix)

+

mavacamten

1 interaction

Caution Advised

relugolix + mavacamten

caution advised if also combined w/ P-gp inducer: combo may decr. relugolix levels, efficacy (hepatic metabolism induced)

• meropenem
Orgovyx (relugolix)

+

meropenem

1 interaction

Caution Advised

relugolix + meropenem

caution advised: combo may decr. relugolix levels, efficacy (P-gp-mediated transport possibly induced)

• modafinil
Orgovyx (relugolix)

+

modafinil

1 interaction

Caution Advised

relugolix + modafinil

caution advised if also combined w/ P-gp inducer: combo may decr. relugolix levels, efficacy (hepatic metabolism induced)

• nafcillin
Orgovyx (relugolix)

+

nafcillin

1 interaction

Caution Advised

relugolix + nafcillin

caution advised if also combined w/ P-gp inducer: combo may decr. relugolix levels, efficacy (hepatic metabolism induced)

• oxcarbazepine
Orgovyx (relugolix)

+

oxcarbazepine

1 interaction

Caution Advised

relugolix + oxcarbazepine

caution advised: combo may decr. relugolix levels, efficacy (P-gp-mediated transport possibly induced)

• pexidartinib
Orgovyx (relugolix)

+

pexidartinib

1 interaction

Caution Advised

relugolix + pexidartinib

caution advised if also combined w/ P-gp inducer: combo may decr. relugolix levels, efficacy (hepatic metabolism induced)

• repotrectinib
Orgovyx (relugolix)

+

repotrectinib

1 interaction

Caution Advised

relugolix + repotrectinib

caution advised if also combined w/ P-gp inducer: combo may decr. relugolix levels, efficacy (hepatic metabolism induced)

• vaborbactam
Orgovyx (relugolix)

+

vaborbactam

1 interaction

Caution Advised

relugolix + vaborbactam

caution advised: combo may decr. relugolix levels, efficacy (P-gp-mediated transport possibly induced)